טוען...
PCSK9 inhibition to reduce cardiovascular disease risk: recent findings from the biology of PCSK9
PURPOSE OF REVIEW: Review novel insights into the biology of proprotein convertase subtilisin/kexin 9 (PCSK9) that may explain the extreme efficiency of PCSK9 inhibition and the unexpected metabolic effects resulting from PCSK9 monoclonal antibody therapy, and may identify additional patients as tar...
שמור ב:
| הוצא לאור ב: | Curr Opin Endocrinol Diabetes Obes |
|---|---|
| Main Authors: | , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
2015
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4384821/ https://ncbi.nlm.nih.gov/pubmed/25692926 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/MED.0000000000000137 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|